Novel Radioligands
Discovery engine of novel radioligand by STR hits unmet molecular targets in Cancer
Starget Pharma is a clinical company developing a new class of Smart Targeted Radioligands (STRs) for precision oncology of hard-to-heal cancers.
Our AI-driven peptide-based discovery engine enables the rapid identification of radioligands that deliver high-energy radiation precisely to tumoral and metastatic cancer cells, while sparing healthy tissues.
We are transforming peptides into next-generation radiopharmaceuticals through our proprietary in silico platform—built upon peptide Backbone Dynamics. This platform simulates and optimizes 3D molecular conformations to identify drug-like radioligand candidates with exceptional affinity, selectivity, and pharmacokinetic properties.
Starget is committed to advancing the science of radiopharmaceuticals and providing new hope to cancer patients worldwide.
Targeted molecular radiotherapy is a cutting-edge, clinically validated approach in nuclear oncology for advanced metastatic cancers.
This form of precision medicine uses the same molecular tracer for both diagnosis and therapy, enabling the detection and targeted destruction of tumors. By combining high specificity with therapeutic payloads, radioligands expand the treatment window for patients with few other options.
Recently approved radioligands have demonstrated remarkable results in cancers such as prostate and neuroendocrine tumors. Starget’s AI-enhanced platform is poised to accelerate this progress, making these innovations accessible faster and at scale.
Radioligands are composed of two parts: a radionuclide (the radioactive payload) and a ligand (often a peptide) that targets cancer cells.
Leveraging our AI-powered peptide Backbone Dynamics platform, we engineer ligands with enhanced 2D and 3D properties for superior drug-like behavior. Our in silico platform optimizes peptide folding and stability, accelerating the identification of high-affinity, selective, and metabolically stable candidates.
These advanced radioligands act as smart molecular vehicles—delivering potent radiation precisely to tumors, maximizing efficacy while minimizing systemic toxicity.
Explore Our Technology
Proprietary core technology for rapid discovery and design of novel druggable STRs
Explore Our TechnologyDiscovery engine of novel radioligand by STR hits unmet molecular targets in Cancer
Rapid in-silico discovery of novel peptide-based Radioligands
Propriety Peptide Backbone Cyclization Technology Boosting STRs drugability
Fast discovery from virtual screening, to radioligand wet lab screening to humans
Multiple peptide-base radioligand programs for diverse cancers
Engineered 2D/3D peptides tailored for affinity, selectivity and bioavailability
Founded in 2019, Starget brings together peptide drug design, nuclear oncology, and AI. Our leadership includes experts in medicinal chemistry, radiopharmaceutical sciences, AI and biotechnology entrepreneurship.
Our mission is rooted in addressing the challenge of designing radioligands with drug-like precision across diverse cancer types.
Meet the team